You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

305 Results
Regimen
Cancer Type:
Gastrointestinal, 
Anus
Intent: Palliative
Apr 2023
Regimen
Cancer Type:
Gastrointestinal, 
Hepatobiliary / Liver / Bile Duct
Intent: Palliative
Apr 2023
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal
Intent: Palliative
Dec 2025
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal
Intent: Palliative
Dec 2025
Regimen
Intent: Adjuvant
Funding:
New Drug Funding Program
    Trastuzumab Emtansine - Adjuvant Treatment for Early Breast Cancer
Oct 2023
Drug
Other Name(s): Besponsa®
Jul 2023
Regimen
Cancer Type:
Gynecologic, 
Gestational Trophoblastic Disease
Intent: Adjuvant, Curative
Dec 2025
Regimen
Intent: Curative, Adjuvant
Funding:
New Drug Funding Program
    Trastuzumab (Biosimilar) - Adjuvant Treatment for Breast Cancer
Apr 2023
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Intent: Palliative
Funding:
Exceptional Access Program
    aXitinib - In combination with pembrolizumab for first-line advanced or metastatic renal cell carcinoma
New Drug Funding Program
    Pembrolizumab - In Combination with Axitinib for First Line Advanced or Metastatic Renal Cell Carcinoma
Aug 2023
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Intent: Palliative
Funding:
ODB - General Benefit
    everolimus
Dec 2025
Drug
Other Name(s): Verzenio®
Updated
Dec 2025
Guidelines and Advice
Jan 2023

Pages